HomeCompareUSRD vs MRK

USRD vs MRK: Dividend Comparison 2026

USRD yields 0.45% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $10.4K in total portfolio value
10 years
USRD
USRD
● Live price
0.45%
Share price
$31.29
Annual div
$0.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.3K
Annual income
$46.16
Full USRD calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — USRD vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodUSRDMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, USRD + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
USRD pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

USRD
Annual income on $10K today (after 15% tax)
$38.10/yr
After 10yr DRIP, annual income (after tax)
$39.24/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, MRK beats the other by $768.51/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of USRD + MRK for your $10,000?

USRD: 50%MRK: 50%
100% MRK50/50100% USRD
Portfolio after 10yr
$25.5K
Annual income
$498.23/yr
Blended yield
1.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

USRD
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

USRD buys
0
MRK buys
0
No recent congressional trades found for USRD or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricUSRDMRK
Forward yield0.45%3.25%
Annual dividend / share$0.14$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR0%8.2%
Portfolio after 10y$20.3K$30.7K
Annual income after 10y$46.16$950.29
Total dividends collected$455.00$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: USRD vs MRK ($10,000, DRIP)

YearUSRD PortfolioUSRD Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$10,745$44.83$11,192$351.54$447.00MRK
2$11,542$45.02$12,524$392.70$982.00MRK
3$12,395$45.19$14,015$438.65$1.6KMRK
4$13,308$45.36$15,682$489.96$2.4KMRK
5$14,285$45.51$17,547$547.23$3.3KMRK
6$15,331$45.66$19,632$611.16$4.3KMRK
7$16,450$45.80$21,963$682.53$5.5KMRK
8$17,647$45.92$24,571$762.18$6.9KMRK
9$18,929$46.04$27,486$851.08$8.6KMRK
10$20,300$46.16$30,745$950.29$10.4KMRK

USRD vs MRK: Complete Analysis 2026

USRDStock

The index is designed to provide exposure to U.S. companies in the large- and mid- capitalization segments that rank in the top 50 companies based on the index Provider’s R&D intensity metric. The fund will invest, under normal circumstances, at least 80% of its net assets, plus the amount of any borrowings for investment purposes, in securities that comprise the index. The fund is non-diversified.

Full USRD Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this USRD vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

USRD vs SCHDUSRD vs JEPIUSRD vs OUSRD vs KOUSRD vs MAINUSRD vs JNJUSRD vs ABBVUSRD vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.